Skip to main content

Advertisement

Log in

Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the intraocular pressure (IOP)-reducing effects and safety of 0.0015% tafluprost ophthalmic solution (tafluprost) in normal-tension glaucoma (NTG) patients with an IOP of 16 mmHg or less.

Methods

NTG patients with a baseline IOP of 16 mmHg or less were enrolled for a one-eye study in which tafluprost was applied once daily for 12 weeks. The presence of adverse drug reactions and the cumulative incidence of adverse events were also investigated.

Results

Among the 44 enrolled patients, 41/44 (93.2%) eyes completed the study. The baseline IOP was 13.2 ± 1.3 mmHg in the study eyes and 13.0 ± 1.3 mmHg in the fellow eyes, which was not statistically significant (P = 0.9173, Student’s t test). The values obtained for IOP in the study eyes versus fellow eyes were 10.2 ± 1.6 versus 12.1 ± 1.5 mmHg at week 12. The IOP difference between the study eyes and the fellow eyes was statistically significant (P < 0.0001, Student’s t test). The cumulative incidence of adverse events was 58.5% by week 12. Ocular itching was the most frequently observed adverse event (29.3%). All adverse events were clinically tolerable.

Conclusions

Tafluprost induced significant IOP reductions in NTG patients with a baseline IOP of 16 mmHg or less without raising any safety concerns.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Yamamoto T, Iwase A, Araie M, Suzuki Y, Abe H, Shirato S, et al. The Tajimi Study report 2. Ophthalmology. 2005;112:1661–9.

    Article  PubMed  Google Scholar 

  2. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505.

    Google Scholar 

  3. Japan Glaucoma Society. The Japan glaucoma society guidelines for glaucoma (2nd edition). Nippon Ganka Gakkai Zasshi. 2006;110:777–814.

  4. Tomita G, Araie M, Kitazawa Y, Tsukahara S. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye (London). 2004;18:984–9.

    Article  CAS  Google Scholar 

  5. Kondo N, Sawada A, Yamamoto T, Taniguchi T. Correlation between individual differences in intraocular pressure reduction and outflow facility due to latanoprost in normal-tension glaucoma patients. Jpn J Ophthalmol. 2006;50:20–4.

    Article  PubMed  Google Scholar 

  6. Ang GS, Kersey JP, Shepstone L, Broadway DC. The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial. Br J Ophthalmol. 2008;92:1129–33.

    Article  PubMed  CAS  Google Scholar 

  7. Nakajima T, Matsugi T, Goto W, Kageyama M, Mori N, Matsumura Y, et al. New fluoroprostaglandin F derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003;26:1691–5.

    Article  PubMed  CAS  Google Scholar 

  8. Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767–76.

    Article  PubMed  CAS  Google Scholar 

  9. Kuwayama Y, Komemushi S. Phase III confirmatory study of 0.0015% DE-085(tafluprost) ophthalmic solution as compared to 0.005% latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Atarashii Ganka. 2008;25:1595–602 (in Japanese).

    Google Scholar 

  10. Uusitalo H, Pillunat LE, Ropo A, On Behalf of the Phase III Study Investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010;88:12–9.

    Article  PubMed  CAS  Google Scholar 

  11. Traverso CE, Ropo A, Papadia M, Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010;26:97–104.

    Article  PubMed  CAS  Google Scholar 

  12. Egorov E, Ropo A, On Behalf of the Investigators. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur J Ophthalmol. 2009;19:214–22.

    PubMed  Google Scholar 

  13. Kuwayama Y, Komemushi S. Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study. Nippon Ganka Gakkai Zasshi. 2010;114:436–43 (in Japanese).

    Google Scholar 

  14. Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of primary open-angle glaucoma in Japanese, The Tajimi Study. Ophthalmology. 2004;111:1641–8.

    PubMed  Google Scholar 

  15. Yamazaki S, Nanno M, Kimura T, Suzumura H, Yoshikawa K. Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost. Jpn J Ophthalmol. 2010;54:7–14.

    Article  PubMed  Google Scholar 

  16. Ahmed MB, William GH. One-minute Schirmer test with anesthesia. Cornea. 2003;22:285–7.

    Article  Google Scholar 

  17. Suh MH, Park KH, Kim DM. Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Jpn J Ophthalmol. 2009;53:18–23.

    Article  PubMed  Google Scholar 

  18. Kjellgren D, Douglas G, Mikelberg FS, Drance SM, Alm A. The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmol Scand. 1995;73:233–6.

    Article  PubMed  CAS  Google Scholar 

  19. Mckibbin M, Menage MJ. The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. Eye. 1999;13:31–4.

    Article  PubMed  Google Scholar 

  20. Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol. 2006;50:153–7.

    Article  PubMed  CAS  Google Scholar 

  21. Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G, et al. An evaluation of the rate of nonresponders to latanoprost therapy. J Glaucoma. 2006;15:238–43.

    Article  PubMed  Google Scholar 

  22. Zimmerman TJ, Stewart WC, Latanoprost Axis Study Group. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther. 2003;19:405–15.

    Article  PubMed  CAS  Google Scholar 

  23. Kitazawa Y, Latanoprost Study Group. An open-label multicenter study on the efficacy and safety of topical use of latanoprost for 156 weeks. Rinsho Ganka (Jpn J Clin Ophthalmol). 2006;60:2047–54 (in Japanese).

  24. Honrubia F, Garacia-Sanchez J, Polo V, Martinez de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009;93:316–21.

    Article  PubMed  CAS  Google Scholar 

  25. Denis P, Baudouin C, Bron A, Nordmann JP, Renard JP, Rouland JF, et al. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmol. 2010;10:4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tadashi Nakano.

About this article

Cite this article

Nakano, T., Yoshikawa, K., Kimura, T. et al. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less. Jpn J Ophthalmol 55, 605–613 (2011). https://doi.org/10.1007/s10384-011-0082-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-011-0082-7

Keywords

Navigation